東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back to Search results for [ null ]

Switch To: Labeled | MARC Mode | ISBD

Investigating the Clinical Validity ...

Farkona, Sofia.

Linked to FindBook

Google Book

Amazon

博客來

Investigating the Clinical Validity of CUB and Zona Pellucidalike Domain-Containing Protein 1 (CUZD1) in Malignant and Non-Malignant Human Diseases.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Investigating the Clinical Validity of CUB and Zona Pellucidalike Domain-Containing Protein 1 (CUZD1) in Malignant and Non-Malignant Human Diseases./
Author:	Farkona, Sofia.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
Description:	136 p.
Notes:	Source: Dissertations Abstracts International, Volume: 79-10, Section: B.
Contained By:	Dissertations Abstracts International79-10B.
Subject:	Biochemistry. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10744428
ISBN:	9780355813913

Investigating the Clinical Validity of CUB and Zona Pellucidalike Domain-Containing Protein 1 (CUZD1) in Malignant and Non-Malignant Human Diseases.
Farkona, Sofia.

Investigating the Clinical Validity of CUB and Zona Pellucidalike Domain-Containing Protein 1 (CUZD1) in Malignant and Non-Malignant Human Diseases. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 136 p.

Source: Dissertations Abstracts International, Volume: 79-10, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2018.

This item must not be sold to any third party vendors.

CUB and zona pellucida-like domain-containing protein 1 (CUZD1) has been previously shown to be specifically expressed in normal pancreas and was proposed as a candidate biomarker for pancreatic related disorders. Due to the lack of specific reagents and techniques, its levels in tissues and biological fluids have not been extensively examined. We generated mouse monoclonal antibodies against recombinant CUZD1 and used them for the development of an enzyme-linked immunosorbent assay (ELISA). Analysis of various human extracts showed that CUZD1 is measured in high levels in pancreas and at much lower (but detectable) levels in several other tissues. Analysis of biological fluids showed that CUZD1 is detected exclusively in pancreatic juice. CUZD1 has been previously linked to diseases (such as pancreatitis, ovarian cancer and IBD) but it is currently unknown if the expression levels of this antigen are elevated in any of the aforementioned or other disorders. Analysis of a large number of serum samples from patients with various malignant and benign disorders showed that CUZD1 levels were elevated in patients with ovarian cysts but not ovarian cancer. CUZD1 is a pancreas-specific protein but it is unclear if its expression is elevated in malignant conditions of the pancreas. IHC staining of pancreatic ductal adenocarcinoma (PDAC) and acinar cell carcinoma (ACC) tissue sections revealed that CUZD1 protein was highly expressed in ACC but not in PDAC. CUZD1 is one of the targets of pancreatic autoantibodies (PABs) which have been emerged as possible biomarkers for Inflammatory Bowel Disease (IBD). Data assessing the diagnostic significance of CUZD1 autoantibodies in patients with IBD are scarce, mainly due to the lack of high throughput techniques for their detection. We developed an ELISA targeting CUZD1 autoantibodies and used it to analyze 200 serum samples from IBD patients and 129 patients assessed for various autoimmune diseases (vADs). CUZD1 autoantibodies were detected in 16% of CrD patients in 9% of UC patients and in less than 5% of patients being tested for vADs. In conclusion, this thesis encompasses the development and validation of analytical techniques targeting CUZD1 antigen and CUZD1 autoantibodies. These tools can facilitate future investigations aiming to delineate the role of CUZD1 in physiology and pathobiology.

ISBN: 9780355813913Subjects--Topical Terms:

518028
Biochemistry.

Investigating the Clinical Validity of CUB and Zona Pellucidalike Domain-Containing Protein 1 (CUZD1) in Malignant and Non-Malignant Human Diseases.
LDR:03558nmm a2200325 4500 001 2210283
005 20191121124158.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780355813913
035 $a (MiAaPQ)AAI10744428
035 $a (MiAaPQ)toronto:17156
035 $a AAI10744428
040 $a MiAaPQ $c MiAaPQ
100 1 $a Farkona, Sofia. $3 3437425
245 1 0 $a Investigating the Clinical Validity of CUB and Zona Pellucidalike Domain-Containing Protein 1 (CUZD1) in Malignant and Non-Malignant Human Diseases.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 136 p.
500 $a Source: Dissertations Abstracts International, Volume: 79-10, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Diamandis, Eleftherios P.;Blasutig, Ivan M.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2018.
506 $a This item must not be sold to any third party vendors.
520 $a CUB and zona pellucida-like domain-containing protein 1 (CUZD1) has been previously shown to be specifically expressed in normal pancreas and was proposed as a candidate biomarker for pancreatic related disorders. Due to the lack of specific reagents and techniques, its levels in tissues and biological fluids have not been extensively examined. We generated mouse monoclonal antibodies against recombinant CUZD1 and used them for the development of an enzyme-linked immunosorbent assay (ELISA). Analysis of various human extracts showed that CUZD1 is measured in high levels in pancreas and at much lower (but detectable) levels in several other tissues. Analysis of biological fluids showed that CUZD1 is detected exclusively in pancreatic juice. CUZD1 has been previously linked to diseases (such as pancreatitis, ovarian cancer and IBD) but it is currently unknown if the expression levels of this antigen are elevated in any of the aforementioned or other disorders. Analysis of a large number of serum samples from patients with various malignant and benign disorders showed that CUZD1 levels were elevated in patients with ovarian cysts but not ovarian cancer. CUZD1 is a pancreas-specific protein but it is unclear if its expression is elevated in malignant conditions of the pancreas. IHC staining of pancreatic ductal adenocarcinoma (PDAC) and acinar cell carcinoma (ACC) tissue sections revealed that CUZD1 protein was highly expressed in ACC but not in PDAC. CUZD1 is one of the targets of pancreatic autoantibodies (PABs) which have been emerged as possible biomarkers for Inflammatory Bowel Disease (IBD). Data assessing the diagnostic significance of CUZD1 autoantibodies in patients with IBD are scarce, mainly due to the lack of high throughput techniques for their detection. We developed an ELISA targeting CUZD1 autoantibodies and used it to analyze 200 serum samples from IBD patients and 129 patients assessed for various autoimmune diseases (vADs). CUZD1 autoantibodies were detected in 16% of CrD patients in 9% of UC patients and in less than 5% of patients being tested for vADs. In conclusion, this thesis encompasses the development and validation of analytical techniques targeting CUZD1 antigen and CUZD1 autoantibodies. These tools can facilitate future investigations aiming to delineate the role of CUZD1 in physiology and pathobiology.
590 $a School code: 0779.
650 4 $a Biochemistry. $3 518028
650 4 $a Health sciences. $3 3168359
690 $a 0487
690 $a 0566
710 2 $a University of Toronto (Canada). $b Laboratory Medicine and Pathobiology. $3 3193014
773 0 $t Dissertations Abstracts International $g 79-10B.
790 $a 0779
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10744428